23011726|t|The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease.
23011726|a|Alzheimer's disease (AD) has been shown to involve desensitised insulin receptor (IR) signalling. Liraglutide, a novel glucagon-like peptide 1 (GLP-1) analogue that facilitates insulin signalling, is currently approved for use in type 2 diabetes mellitus. In the present study, we show that distinctive alterations in the localisation and distribution of the IR and increased levels of insulin receptor substrate (IRS)-1 phosphorylated at serine 616 (IRS-1 pS(616)), a key marker of insulin resistance, are associated with amyloid-beta plaque pathology in the frontal cortex of a mouse model of AD, APPSWE/PS1dE9. Altered IR status in APPSWE/PS1dE9 is most evident in extracellular deposits with the appearance of dystrophic neurites, with significantly increased IRS-1 pS(616) levels detected within neurons and neurites. The IR and IRS-1 pS(616) changes occur in the vicinity of all plaques in the APPSWE/PS1dE9 brain, and a significant upregulation of astrocytes and microglia surround this pathology. We show that liraglutide treatment for 8 weeks at 25 nmol/kg body weight i.p. once daily in 7-month-old mice significantly decreases IR aberrations in conjunction with a concomitant decrease in amyloid plaque load and levels of IRS-1 pS(616). Liraglutide also induces a highly significant reduction in astrocytosis and microglial number associated with both plaques and IR pathology. The amelioration of IR aberrations and attenuation of IRS-1 pS(616) upregulation, plaque and glial activation in APPSWE/PS1dE9 mice treated with liraglutide support the investigation of the therapeutic potential of liraglutide and long-lasting GLP-1 agonists in patients with AD.
23011726	4	12	diabetes	Disease	MESH:D003920
23011726	51	67	insulin receptor	Gene	16337
23011726	174	179	mouse	Species	10090
23011726	189	208	Alzheimer's disease	Disease	MESH:D000544
23011726	210	229	Alzheimer's disease	Disease	MESH:D000544
23011726	231	233	AD	Disease	MESH:D000544
23011726	274	290	insulin receptor	Gene	16337
23011726	292	294	IR	Gene	16337
23011726	329	352	glucagon-like peptide 1	Gene	2641
23011726	354	359	GLP-1	Gene	2641
23011726	387	394	insulin	Gene	3630
23011726	440	464	type 2 diabetes mellitus	Disease	MESH:D003924
23011726	569	571	IR	Gene	16337
23011726	596	630	insulin receptor substrate (IRS)-1	Gene	16367
23011726	661	666	IRS-1	Gene	16367
23011726	693	711	insulin resistance	Disease	MESH:D007333
23011726	790	795	mouse	Species	10090
23011726	805	807	AD	Disease	MESH:D000544
23011726	809	815	APPSWE	CellLine	CVCL:D650
23011726	832	834	IR	Gene	16337
23011726	974	979	IRS-1	Gene	16367
23011726	1037	1039	IR	Gene	16337
23011726	1044	1049	IRS-1	Gene	16367
23011726	1319	1323	mice	Species	10090
23011726	1348	1350	IR	Gene	16337
23011726	1409	1416	amyloid	Disease	MESH:C000718787
23011726	1443	1448	IRS-1	Gene	16367
23011726	1517	1529	astrocytosis	Disease	MESH:D005911
23011726	1585	1587	IR	Gene	16337
23011726	1619	1621	IR	Gene	16337
23011726	1653	1658	IRS-1	Gene	16367
23011726	1726	1730	mice	Species	10090
23011726	1843	1848	GLP-1	Gene	2641
23011726	1861	1869	patients	Species	9606
23011726	1875	1877	AD	Disease	MESH:D000544
23011726	Association	MESH:D005911	16337
23011726	Association	MESH:D000544	16337
23011726	Association	MESH:D007333	16367
23011726	Association	16337	16367

